Cancer Charities Win the Humane Charity Seal of Approval
PCRM thanks actor Noah Wyle, also known as Dr. John Carter of NBC’s long-running series ER, for his support of the Humane Charity Seal of Approval program. PCRM recently ran ads featuring Noah in theater magazines across the United States and will soon launch a print public service ad campaign targeting nearly 7,000 outlets.
Two cancer charities—the Avon Foundation and the Cancer Treatment Resource Foundation—join the more than 200 charitable organizations that have been awarded the Humane Charity Seal of Approval. Since its creation in 2000, the Humane Seal has been awarded to charities committed to caring for people in a unique way. With concerns ranging from physical and mental disabilities to birth defects, trauma, and childrens’ health issues, these organizations are stellar examples of the progress that can be made with effective medical services and research methods that exclude animal experimentation.
The Avon Breast Cancer Crusade
The Avon Foundation meets the needs of women facing breast cancer by funding research, clinical care, support, and education, raising more than $250,000,000 worldwide from 1993 to 2003. Along the way, it ensures that no breast cancer patients are left behind. With special emphasis on low-income, elderly, and minority women, the foundation provides vital women’s services in 50 countries. “We were delighted to have been awarded the Humane Seal,” said Mary Quinn, senior manager, Avon Foundation. For more information about donating, please visit www.avoncrusade.com. To learn about participating in an Avon Walk for Breast Cancer, please visit www.AvonWalk.org.
The Cancer Treatment Resource Foundation
Since its beginning in 1992, the Cancer Treatment Resource Foundation (CTRF) has funded over 50 clinical trials totaling over $15 million. Extensive corporate underwriting, particularly from Cancer Treatment Centers of America, allows for 99 cents of every dollar donated to be applied directly to research. CTRF is currently funding innovative research programs across the globe, including a lung cancer vaccine study at the University of Kentucky, an investigation of a new treatment for non-Hodgkin’s lymphoma, the introduction of interleukin-2 as a prostate cancer therapy at Malpighi Hospital in Bologna, Italy, and a study of antioxidants and cancer risk factors at the Faculty of Chemistry in Montevideo, Uruguay.
“It is important for CTRF to have the Humane Charity Seal of Approval,” says CTRF President Fern Ingber. “The CTRF is recognized as a worldwide leader and catalyst for the development of responsive, patient-centered cancer treatment options while aggressively working towards a cure. The fact that we conduct clinical trials without engaging in animal experimentation only makes our efforts more relevant and groundbreaking.”